trial · primary record
Lebrikizumab
Atopic Dermatitis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 338 |
| Primary completion | 2029-04 |
| Primary endpoint | Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs) |
| Registry ID | NCT05735483 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:05.478Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05735483
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.